China's updated ADR reporting rules to increase manufacturers' obligations
This article was originally published in SRA
China's Ministry of Health has issued revised rules on the monitoring and reporting of adverse drug reactions1. The revised provisions will apply from 1 July and are likely to "significantly increase" the regulatory obligations of pharmaceutical manufacturers, according to legal experts at Sidley Austin2.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.